Tampa medical device firm achieves major milestone
August 11, 2020 - Wearable technology, designed to treat depression, has won a “breakthrough device” designation from the U.S. Food and Drug Administration. The Relivion system, developed by Neurolief, is a non-invasive multi-channel brain neuromodulation technology. It is designed as an additional treatment to pharmaceutical management of major depressive disorder in adults who have not achieved satisfactory improvement from antidepressant medications, a news release said. Gaining FDA recognition bolsters an upcoming study on Relivion, said Chris Richardson, chairman of Neurolief, an Israeli company with U.S. operations in Tampa. He called the move a major milestone for Neurolief. Read more about Neurolief and the Relivion system in the St. Pete Catalyst Venture section here.